Evaluation of the 2021 European Society of Cardiology guidelines in pre-existing right bundle branch block patients undergoing transcatheter aortic valve implantation with a balloon-expandable valve

Toshiaki Isogai, Iryna Dykun, Ankit Agrawal, Shashank Shekhar, Khaldoun G. Tarakji, Oussama M. Wazni, Ankur Kalra, Amar Krishnaswamy, Grant W. Reed, Samir R. Kapadia, and Rishi Puri

1Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195, USA; and 2Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University of Duisburg-Essen, Essen, Germany

Aims
The 2021 European Society of Cardiology guidelines recommend early pacemaker implantation in pre-existing right bundle branch block (RBBB) patients who develop PR prolongation or QRS axis change after transcatheter aortic valve implantation (TAVI). We aimed to evaluate this recommendation in TAVI recipients with a balloon-expandable valve (BEV).

Methods and results
We retrospectively reviewed 188 pre-existing RBBB patients without pre-existing permanent pacemaker (PPM) who underwent TAVI with a BEV at our institution in 2015–19. Patients who developed high-degree atrioventricular block (HAVB) during TAVI or within 24 h post-TAVI were excluded. Eligible patients were divided according to the guideline-directed criteria (PR interval $\geq$20 ms and/or QRS axis change). Patients who met the criteria (n = 102, 54.3%), compared with those who did not (n = 86), had a higher prevalence of baseline right axis deviation and were more likely to have received a larger valve with greater oversizing. The 30-day delayed HAVB rate did not differ significantly between the groups (3.9% vs. 4.7%, $P$ = 1.00; odds ratio = 0.84, 95% confidence interval = 0.20–3.45). There was also no significant difference in terms of death (5.0% vs. 8.4% at 1 year; overall log-rank $P$ = 0.94) or a composite of death or PPM implantation (14.8% vs. 16.6% at 1 year; overall log-rank $P$ = 0.94) during follow-up post-TAVI. The majority of PR prolongations (79.4%) and QRS axis changes (52.0%) regressed within the following 24 h.

Conclusion
The present data did not demonstrate an association of significant changes in PR interval or QRS axis with heightened delayed HAVB risk in BEV recipients with pre-existing RBBB. Prospective studies are warranted to confirm these findings.

* Corresponding author. Tel: +1 216 444 6731, Fax: +1 216 445 6173, Email: puri@ccf.org

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Graphical Abstract

2021 ESC guideline for cardiac pacing after TAVI

Pre-existing RBBB with post-procedure conduction disturbance (PR prolongation or QRS axis change) → Early (immediate post-procedure or within 24 hrs) PPM implantation should be considered (Class Ila, Evidence Level B).

188 patients with pre-existing RBBB who underwent TAVI with a BEV without developing early (≤24 hrs) HAVB

ΔPR interval ≥20 ms or QRS axis change within 24 hrs post-TAVI

Yes

102 (54.3%)

79.4% of PR prolongations and 52.0% of QRS axis changes regressed within the following 24 hrs.

No

86 (45.7%)

Delayed HAVB within 30 days

4 (3.9%) P = 1.00 4 (4.7%)

PPM/ICD implantation for any indication within 30 days

6 (5.9%) P = 0.76 4 (4.7%)

(A) Death

(B) Death or PPM/ICD implantation

Keywords

Transcatheter aortic valve implantation • Right bundle branch block • High-degree atrioventricular block
Introduction

Owing to encouraging results from pivotal randomized studies during the last decade, transcatheter aortic valve implantation (TAVI) is a minimally invasive standard treatment for symptomatic severe aortic stenosis.1 Despite the enhanced safety of TAVI, there has been a relatively stable incidence (~10%) of post-TAVI permanent pacemaker (PPM) requirements in recent years.2 Amongst several patient factors associated with post-TAVI PPM risk, pre-existing right bundle branch block (RBBB) is the most consistent and powerful predictor.3 Therefore, a specific post-TAVI management algorithm is generally recommended for pre-existing RBBB recipients due to the heightened risk of high-degree atrioventricular block (HAVB) post-TAVI.4

The 2021 European Society of Cardiology (ESC) cardiac pacing guidelines for the first time offered recommendations post-TAVI, whereby early (immediate post-procedure or within 24 h) PPM implantation should be considered for patients with pre-existing RBBB who develop any further conduction disturbance (defined as transient HAVB, PR prolongation, or QRS axis change) during or after TAVI (Class IIa, Evidence Level B).5 Such recommendations seem entirely reasonable in patients with pre-existing RBBB who develop peri-procedural HAVB, given the elevated risk of sudden cardiac death due to recurrent events after discharge.6,7 However, the recommendation has yet to be validated in patients with pre-existing RBBB who developed PR prolongation or QRS axis change (in the absence of peri-procedural HAVB) due to a lack of supporting data. Balloon-expandable valves (BEVs) are associated with lower PPM risk compared with self-expanding valves (SEVs).8 Therefore, this study sought to evaluate the ESC guideline recommendation for BEV recipients.

Methods

Study design

This was a retrospective study conducted at the Cleveland Clinic between January 2015 and December 2019. Data on patient characteristics, electrocardiogram (ECG), imaging data, procedural characteristics, and outcomes were collected from our prospective institutional registries or were manually collected from electronic medical records. Post-discharge outcomes were collected through our institutional electronic medical records in Epic (Epic Systems Corporation, Verona, WI, USA) as well as outside hospital records using ‘Care Everywhere’ function in Epic. The study was approved by the institutional review board of the Cleveland Clinic with a waiver of informed consent owing to the retrospective nature of the study.

Patient selection

This study included consecutive adult patients aged ≥18 years who underwent TAVI at the Cleveland Clinic between January 2015 and December 2019. At our institution, no patient received a ‘prophylactic’ PPM during pre-TAVI assessment. The exclusion criteria were (i) patients with a pre-existing cardiac implantable electronic device, (ii) those without pre-existing RBBB (QRS duration ≥120 ms), (iii) those who received a SEV, and (iv) those who already developed HAVB during TAVI or within 24 h post-TAVI. HAVB includes persistent complete heart block (CHB), transient CHB, and advanced atrioventricular block. Advanced atrioventricular block was defined as (i) Mobitz type II 2nd-degree atrioventricular block or 2:1 or more atrioventricular block in the presence of a QRS duration ≥120 ms, or (ii) a prolonged pause (>3 s) or a fixed slow (<50 b.p.m.) ventricular response rate in the setting of atrial fibrillation. Eligible patients in the present study were those with pre-existing RBBB who underwent TAVI with a BEV without developing an early (<24 h) HAVB. In this study, automated measurements of PR interval, QRS duration, and QRS axis based on an algorithm devised by GE Healthcare (Chicago, IL, USA) were used. All ECG measurements and tracings were reviewed, verified, and interpreted by two experienced cardiologists according to the standard definitions and guidelines by the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS) recommendations.9,10 Since the ESC guidelines do not stipulate a minimum increase in PR interval for the criterion of PR prolongation, this study defined PR prolongation as ≥20 ms increase (i.e. ΔPR interval ≥20 ms) from baseline to within 24 h post-TAVI in reference to a recent expert consensus document.11 The standard definitions by the ACC/AHA/HRA recommendations were used to define three QRS axis categories: normal axis (QRS axis: −30° to 90°), left-axis deviation (<−30°), and right-axis deviation (>90°). Since the ESC guidelines also do not define QRS axis change, this study defined QRS axis change as the change from one baseline axis category to another axis category within 24 h post-TAVI for the main analysis. The eligible patients were divided into two groups according to the presence or absence of the ESC guideline-directed ECG change (PR prolongation and/or QRS axis change).

Baseline and procedural characteristics

Patient demographics, prior history and comorbidity, echocardiographic parameters, aortic valve data, ECG findings (baseline and post-TAVI), and procedural details were collected for the present analyses. Aortic valve annular parameters were measured using ECG-gated computed tomography (CT) images with contrast pre-TAVI (or cardiac magnetic resonance imaging in patients without pre-TAVI contrast CT due to poor renal function). Calcium score of aortic valve leaflets was quantified using ECG-gated contrast CT images pre-TAVI, where a pre-specified threshold was established to account for the hyperdensity of the applied contrast medium according to a prior study.12 Calcification at the left ventricular outflow tract was also assessed using pre-TAVI CT images. These imaging data were collected using Aquarius iNtuition (TeraRecon Inc., Foster City, CA, USA). Oversizing was calculated based upon the methods described in a prior study.13 Implantation depth of the BEV relative to the base of non-coronary cusp (NCC) was defined as the distance between the bottoms of the NCC and the valve stent frame in the final right anterior oblique caudal aortic root angiogram and was measured using SyngoDynamics (Siemens Healthcare, Malvern, PA, USA).

Outcome measures

The primary outcomes of interest were delayed HAVB and PPM or implantable cardioverter-defibrillator (ICD) implantation within 30 days post-TAVI. Delayed HAVB was defined as any HAVB episode occurring after 24 h and within 30 days post-TAVI. At our institution, the electrophysiology team decided on the need for PPM or ICD implantation in compliance with the ACC/AHA/HRA guidelines.14 The secondary outcomes were death and PPM/ICD implantation during follow-up. Each patient was followed up until death or the date of the latest visit (in-person or online) or hospitalization on their medical records. Two experienced cardiologists reviewed all death cases and determined whether each death was a sudden death or not. Then, the incidences of sudden death and a composite of sudden death or PPM/ICD implantation were assessed.
Statistical analysis
Categorical variables were presented as numbers and percentages and were compared using the Fisher’s exact test or χ² test. Continuous variables were presented as mean ± standard deviation or median and interquartile range (IQR) and were compared using Student’s t-test or Mann–Whitney U test as appropriate. We compared the patient characteristics and outcomes between patients with and without ΔPR interval ≥20 ms and/or QRS axis change. We also examined the consistency of outcome results in the cohort excluding Sapien XT recipients. As a sensitivity analysis, we redefined QRS axis change as an absolute change of ≥30° in QRS axis degree (i.e. absolute ΔQRS axis ≥30°) and recategorized the patients to compare outcomes. The agreement between the two different definitions of QRS axis change was assessed with the kappa coefficient.

Univariable analysis was conducted to assess potential predictors of delayed HAVB. Predictive values for the guideline-directed ECG change and procedural factors in predicting delayed HAVB were also evaluated. Death and a composite of death or PPM/ICD implantation during follow-up were compared between patients with or without the ECG change using Kaplan–Meier curves with the log-rank test. A two-sided P-value of <0.05 was considered significant in all hypothesis tests. All statistical analyses were conducted using IBM SPSS Statistics, version 27 (IBM Corp., Armonk, NY, USA).

Results

Study patients
Figure 1 shows the patient selection for the present study. A total of 188 eligible patients with pre-existing RBBB who underwent TAVI with a BEV without developing early (<24 h) HAVB were identified. Overall, the mean age was 79.6 ± 9.2 years; 24.5% were women; the median Society of Thoracic Surgeons-Predicted Risk of Mortality was 4.59% (IQR 3.26–7.87%); transfemoral approach was used in 93.6%. In total, 102 (54.3%) patients had the guideline-directed ECG change of PR prolongation and/or QRS axis change (52 developed ΔPR interval ≥20 ms alone, 34 had developed QRS axis change alone, and 16 developed both changes) (Supplementary material online, Table S1). Patients with the ECG change, as compared to those without, had a higher prevalence of baseline right axis deviation, were more likely to have received a larger (29 mm) valve with a greater degree

Figure 1 Patient selection. CIED, cardiac implantable electronic device; HAVB, high-degree atrioventricular block; RBBB, right bundle branch block; TAVI, transcatheter aortic valve implantation.
of valve oversizing (Table 1). Other characteristics did not differ significantly between the two groups. No patient died within 30 days after TAVI.

**Delayed high-degree atrioventricular block and permanent pacemaker implantation**

The overall delayed HAVB rate was 4.3% (n = 8). There was no significant difference in the delayed HAVB rate (3.9% vs. 4.7%, \( P = 1.00 \)) between patients with or without the guideline-directed ECG change (Table 2). All patients who developed delayed HAVB received PPM implantation. In addition, two (2.0%) of the patients with the ECG change received PPM/ICD implantation for indications other than HAVB. There was no significant difference in the 30-day PPM/ICD rate (5.9% vs. 4.7%, \( P = 0.76 \)) between the groups. No other patients experienced bradyarrhythmia-related outpatient visits or readmission within 30 days post-TAVI. In the cohort excluding Sapien XT recipients, there was also no significant difference between patients with (n = 97) or without (n = 82) the ECG change in terms of delayed HAVB (3.1% vs. 4.9%, \( P = 0.70 \)) and 30-day PPM/ICD implantation (5.2% vs. 4.9%, \( P = 1.00 \)), consistent with the main analysis above.

**Table 1** Baseline and procedural characteristics of pre-existing RBBB patients with or without ΔPR interval ≥20 ms or QRS axis change following TAVI

|                          | ΔPR interval ≥20 ms or QRS axis change (n = 102) | Neither ΔPR interval ≥20 ms nor QRS axis change (n = 86) | P-value |
|--------------------------|-----------------------------------------------|----------------------------------------------------------|---------|
| **Baseline characteristics** |                                              |                                                          |         |
| Age (years)              | 79.9 ± 9.0                                    | 79.3 ± 9.4                                               | 0.67    |
| Female                   | 28 (27.5)                                     | 18 (20.9)                                                | 0.31    |
| STS-PROM (%)             | 4.75 (3.25–7.32)                              | 4.56 (3.32–8.02)                                         | 0.85    |
| ESRD on dialysis         | 2 (2.0)                                       | 4 (4.7)                                                  | 0.41    |
| Left ventricular ejection fraction (%)  | 57.3 ± 10.5                                   | 56.7 ± 10.7                                              | 0.71    |
| AV mean gradient (mmHg)  | 42.3 ± 15.0                                   | 43.5 ± 14.3                                              | 0.59    |
| Bicuspid AV              | 7 (6.9)                                       | 3 (3.5)                                                  | 0.35    |
| Degenerated bioprosthetic valve | 5 (4.9)                                     | 10 (11.6)                                                | 0.11    |
| Calcium score of AV leaflets (HU)* | 2117 (1138–3340) [n = 77]  | 2308 (1428–2989) [n = 62]                                 | 0.69    |
| LVOT calcificationb      | 50/96 (52.1)                                  | 38/76 (50.0)                                             | 0.88    |
| **Pre-TAVI baseline ECG findings** |                                              |                                                          |         |
| Atrial fibrillation rhythm | 11 (10.8)                                    | 12 (14.0)                                                | 0.51    |
| First-degree AVB         | 38 (37.3)                                     | 26 (30.2)                                                | 0.36    |
| Bifascicular block       | 30 (29.4)                                     | 22 (25.6)                                                | 0.62    |
| QRS axis category        |                                              |                                                          | 0.030   |
| Normal axis              | 47 (46.1)                                     | 42 (48.8)                                                |         |
| Left-axis deviation      | 42 (41.2)                                     | 42 (48.8)                                                |         |
| Right-axis deviation     | 13 (12.7)                                     | 2 (2.3)                                                  |         |
| PR interval (ms)         | 192 (173–224) [n = 91]                        | 188 (163–215) [n = 72]                                   | 0.30    |
| QRS duration (ms)        | 147 (138–156)                                 | 145 (136–160)                                            | 0.87    |
| **Procedural details**   |                                              |                                                          |         |
| Valve generation         |                                              |                                                          | 1.00    |
| Sapien XT                | 5 (4.9)                                       | 4 (4.7)                                                  |         |
| Sapien 3                 | 97 (95.1)                                     | 82 (95.3)                                                |         |
| Valve size               |                                              |                                                          | 0.047   |
| <23 mm                   | 32 (31.4)                                     | 20 (23.3)                                                |         |
| 26 mm                    | 34 (33.3)                                     | 44 (51.2)                                                |         |
| 29 mm                    | 36 (35.3)                                     | 22 (25.6)                                                |         |
| Pre-dilation             | 17 (16.7)                                     | 18 (20.9)                                                | 0.46    |
| Post-dilation            | 48 (47.1)                                     | 32 (37.2)                                                | 0.19    |
| Oversizing (%)c          | 5.2 (1.0–8.6) [n = 99]                        | 3.1 (0.4–6.9) [n = 81]                                   | 0.025   |
| Implantation depth relative to NCC (mm) | 1.7 (0.9–3.2)                                    | 2.6 (0.8–3.7)                                             | 0.060   |

Values are n (%), n/total n (%), mean ± standard deviation, or median (interquartile range). \( P \)-values are not corrected for multiplicity.

AV, aortic valve; AVB, atrioventricular block; CT, computed tomography; ECG, electrocardiogram; HU, Hounsfield unit; ESRD, end-stage renal disease; LVOT, left ventricular outflow tract; NCC, non-coronary cusp; STS-PROM, Society of Thoracic Surgeons-Predicted Risk of Mortality; TAVI, transcatheter aortic valve implantation.

*Incalculable in 49 patients due to the lack of contrast CT images pre-TAVI or prior bioprosthetic valve.

Unavailable in 16 patients due to the lack of appropriate CT images pre-TAVI or prior bioprosthetic valve.

Unavailable in eight patients because AV annular data were unavailable due to neither contrast CT images nor cardiac magnetic resonance images.
Sensitivity analysis using another definition of QRS axis change
In the sensitivity analysis using another definition of QRS axis change (i.e., an absolute change of ≥30°), 104 (55.3%) patients had the guideline-directed ECG change of ΔPR interval ≥20 ms and/or absolute ΔQRS axis ≥30° (53 had ΔPR interval ≥20 ms alone, 36 had absolute ΔQRS axis ≥30° alone, and 15 had both changes). The agreement between the two different definitions of QRS axis change was moderate (agreement 83.5%; kappa coefficient = 0.58), whereas the agreement between the two overall ECG criteria using ΔPR interval ≥20 ms and different QRS axis change definitions were substantial (agreement 90.4%; kappa coefficient = 0.81). There was no significant difference in delayed HAVB and 30-day PPM/ICD implantation between patients with or without the ECG changes of ΔPR interval ≥20 ms and/or absolute ΔQRS axis ≥30° (Supplementary material online, Table S2), consistent with the main analysis above.

Potential predictors for delayed high-degree atrioventricular block
Univariable logistic regression analyses found no significant association between the presence of the guideline-directed ECG change and delayed HAVB risk (odds ratio = 0.84, 95% confidence interval = 0.20–3.45; P = 0.81). In contrast, pre-dilation (4.81, 1.14–20.26; P = 0.032) and implantation depth relative to the NCC (per 1 mm increase, 1.63, 1.08–2.46; P = 0.020) were significantly associated with an increased risk of delayed HAVB (Table 3). Details of the eight patients who developed delayed HAVB are summarized in Table 4. Seven out of eight HAVB events occurred within 7 days after TAVI. Patients who developed delayed HAVB, as compared with those who did not, were more likely to have undergone pre-dilation (50.0% vs. 17.2%, P = 0.014) and have had a greater implantation depth [2.7 (3.9–4.2) mm vs. 1.9 (0.8–3.4) mm, P = 0.009]. All patients who developed delayed HAVB had an implantation depth of 2.0 mm.

Regression of electrocardiogram changes
Of the 68 patients who developed ΔPR interval ≥20 ms within 24 h post-TAVI, 54 (79.4%) showed ≥20 ms decrease in their PR interval within the following 24 h, of whom 1 patient, who had pre-existing trifascicular block, developed delayed HAVB on post-TAVI Day 2 (Case No. 5 in Table 4). Of the 50 patients who developed QRS axis change within 24 h post-TAVI, 26 (52.0%) demonstrated recovery to baseline QRS axis within the following 24 h, none of whom developed delayed HAVB. When we further divided the patients with ECG changes within 24 h post-TAVI according to persistent ECG change (i.e., changes without ≥20 ms decrease in PR interval or recovery to baseline QRS axis between 24 and 48 h post-TAVI) or not, patients with persistent ECG change (n = 36) had numerically higher rates of delayed HAVB (8.3% vs. 1.5%, P = 0.12) and 30-day PPM/ICD (11.1% vs. 3.0%, P = 0.18) than those without persistent ECG change (n = 66).

Predictive values of electrocardiogram and procedural parameters for delayed high-degree atrioventricular block
ΔPR interval ≥20 ms and QRS axis change within 24 h each showed a low positive predictive value (1.5% and 6.0%, respectively) in predicting delayed HAVB (Table 5). Persistent change of the QRS axis between 24 and 48 h post-TAVI showed a higher positive predictive value (12.5%, 3/24) than that (6.0%) of QRS axis change within 24 h. The combination of pre-dilation and implantation depth also showed a relatively high positive predictive value.

Follow-up outcomes
The median follow-up period after TAVI was 29.4 months (IQR 19.9–41.9 months). Overall, 49 (26.1%) patients died and 22 (11.7%) received PPM/ICD implantation. There was no significant difference between patients with or without the guideline-directed ECG change in terms of death (5.0% vs. 8.4% at 1 year; overall log-rank P = 0.94) or a composite of death or PPM/ICD implantation (14.8% vs. 16.6% at 1 year; overall log-rank P = 0.94) during follow-up (Figure 2). Sudden death occurred in 6 patients during follow-up (3 with the guideline-directed ECG change died on post-TAVI Day 373, 1025, and 1029; 3 without the ECG change died on post-TAVI Day 67, 898, and 1504). There were no significant differences between the groups in terms of sudden death (0.0% vs. 1.3% at 1 year; overall log-rank P = 0.94) and a composite of sudden death or PPM/ICD implantation (9.9% vs. 9.5% at 1 year; overall log-rank P = 0.97).

Table 2  Delayed HAVB and PPM/ICD implantation within 30 days post-TAVI

|                     | ΔPR interval ≥20 ms or QRS axis change (n = 102) | Neither ΔPR interval ≥20 ms nor QRS axis change (n = 86) | P-value |
|---------------------|-------------------------------------------------|--------------------------------------------------------|---------|
| Delayed HAVB        | 4 (3.9)                                         | 4 (4.7)                                                | 1.00    |
| Persistent CHB      | 3 (2.9)                                         | 2 (2.3)                                                | 1.00    |
| Transient CHB       | 1 (1.0)                                         | 1 (1.2)                                                | 1.00    |
| Advanced AVB        | 0 (0.0)                                         | 1 (1.2)                                                | 0.46    |
| PPM/ICD implantation for any indication | 6 (5.9)                                          | 4 (4.7)                                                | 0.76    |
| PPM/ICD implantation for delayed HAVB | 4a (3.9)                                         | 4a (4.7)                                               | 1.00    |
| PPM/ICD implantation for other indications | 2b (2.0)                                          | 0 (0.0)                                                | 0.50    |

CHB, complete heart block; HAVB, high-degree atrioventricular block; ICD, implantable cardioverter-defibrillator; PPM, permanent pacemaker.

aAll patients receive dual-chamber PPMs.
bOne patient received leadless PPM on Day 5 for bifascicular block and atrial fibrillation with slow rate response complicated by syncope with no other identifiable cause, while the other received cardiac resynchronization therapy with defibrillator on Day 27 for new-onset worsening left bundle branch block and low left ventricular ejection fraction.
Discussion

This study evaluated the 2021 ESC guideline recommendations for PPM in BEV-TAVI recipients with pre-existing RBBB. The present analysis failed to show an association of the guideline-directed ECG change (PR segment prolongation or QRS axis change post-TAVI) with delayed HAVB risk in pre-existing RBBB patients. The HAVB and PPM requirements appeared to occur at a similar rate regardless of the presence or absence of the guideline-directed ECG change.

Electrocardiogram changes and delayed high-degree atrioventricular block risk in transcatheter aortic valve implantation recipients with pre-existing right bundle branch block

A recent meta-analysis reported that patients with pre-existing RBBB had a >3-fold higher PPM risk at 30 days post-TAVI than those without pre-existing RBBB (38.1% vs. 11.4%; risk ratio 3.56). Importantly, however, the majority of HAVB events leading to PPM implantation occurred at an early phase (during the TAVI procedure or very shortly thereafter). A Canadian study reported that 88.1% (52/59) of 30-day HAVB events occurred during the TAVI procedure or very shortly thereafter in pre-existing RBBB patients, which was comparable to that (88.2%, 60/68) in the present study. The risk stratification and workflow of pre-existing RBBB patients without developing early HAVB remain key issues, whereby one has to balance prolonged ECG monitoring post-TAVI (and increasing hospital length of stay) with the risk of being discharged home with a subsequent risk of HAVB. The new ESC guidelines incorporated PR prolongation and QRS axis change in the recommendation in light of current knowledge on the post-TAVI HAVB risk. However, the present analysis failed to unravel an association of the guideline ECG change criteria with delayed HAVB risk. One possible reason for this result is that all patients in the present analysis received a BEV.

Table 3  Univariable analyses for delayed HAVB post-TAVI

| Guideline criteria                                      | Odds ratio | 95% CI     | P-value |
|---------------------------------------------------------|------------|------------|---------|
| ΔPR interval ≥20 ms or QRS axis change                  | 0.84       | 0.20–3.45  | 0.81    |
| ΔPR interval ≥ 20 ms (N = 157)                          | 0.32       | 0.03–2.90  | 0.31    |
| QRS axis change                                         | 1.70       | 0.39–7.38  | 0.48    |
| Baseline characteristics                                |            |            |         |
| Age, per 1-year increase                                | 1.00       | 0.93–1.08  | 0.99    |
| Female                                                  | (-)        | (-)        | (-)     |
| STS-PROM, per 1% increase                               | 0.85       | 0.64–1.13  | 0.27    |
| Left ventricular ejection fraction, per 1% increase     | 0.99       | 0.93–1.05  | 0.66    |
| AV mean gradient, per 1 mmHg increase                   | 0.95       | 0.89–1.00  | 0.060   |
| Calcium score of AV leaflets, per 100 HU increase (N = 139) | 0.95      | 0.88–1.02  | 0.18    |
| LVOT calcification (N = 172)                            | 0.56       | 0.13–2.41  | 0.43    |
| Pre-TAVI baseline ECG findings                          |            |            |         |
| Atrial fibrillation rhythm                              | 2.52       | 0.48–13.32 | 0.28    |
| First-degree AVB                                        | 2.00       | 0.48–8.28  | 0.34    |
| Bifascicular block                                      | 0.36       | 0.04–3.01  | 0.35    |
| Procedural details                                      |            |            |         |
| Sapien 3 (vs. Sapien XT)                                | 0.33       | 0.04–2.97  | 0.32    |
| Valve size                                              |            |            |         |
| ≤23 mm                                                  | (-)        | (-)        | (-)     |
| 26 mm                                                   | 1.26       | 0.29–5.48  | 0.76    |
| 29 mm                                                   | Reference  |           |         |
| Pre-dilation                                           | 4.81       | 1.14–20.26 | 0.032   |
| Post-dilation                                          | 0.18       | 0.02–1.52  | 0.12    |
| Oversizing, per 1% increase (N = 180)                   | 1.06       | 0.96–1.19  | 0.26    |
| Implantation depth relative to NCC, per 1-mm increase    | 1.63       | 1.08–2.46  | 0.020   |

AV, aortic valve; AVB, atrioventricular block; CI, confidence interval; ECG, electrocardiogram; HU, Hounsfield unit; LVOT, left ventricular outflow tract; NCC, non-coronary cusp; STS-PROM, Society of Thoracic Surgeons-Predicted Risk of Mortality; TAVI, transcatheter aortic valve implantation.

P-values are not corrected for multiplicity.
## Table 4  Details of patients who developed delayed HAVB post-TAVI

| Case No. | Guideline criteria: DPR interval ≥ 20 ms/QRS axis change within 24 h | Age/sex | STS-PROM (%) | Pre-TAVI PR/QRS duration (ms) | ΔPR/ΔQRS duration within 24 h post-TAVI (ms) | QRS axis degree (°), baseline/post-TAVI | Approach, diseased valve, and implanted prosthesis | Pre-/post-dilation | Implantation depth relative to NCC (mm) | Type and timing of delayed HAVB | Type of implanted device |
|----------|---------------------------------------------------------------------|---------|--------------|------------------------------|-----------------------------------------------|------------------------------------------|---------------------------------------------|-------------------|--------------------------------------|----------------------|--------------------------|
| 1        | No/Yes                                                              | 66 M    | 2.25         | 198/166                      | −6/−6                                         | −36/101                                  | Transaortic, native bicuspid valve, Sapien XT 29 mm | Yes/No            | 6.1                                 | Persistent CHB, Day 3 | Dual-chamber PPM            |
| 2        | No/Yes                                                              | 87 M    | 7.32         | 218/126                      | +4/+2                                         | −21/−42                                  | TF, native tricuspid, S3 26 mm                  | Yes/No            | 4.1                                 | Persistent CHB, Day 5 | Dual-chamber PPM            |
| 3        | No/Yes                                                              | 78 M    | 6.00         | AF/144                       | NA/+16                                       | 61/−74                                   | TF, native tricuspid, S3 26 mm                  | Yes/No            | 4.2                                 | Persistent CHB, Day 6 | Dual-chamber PPM            |
| 4        | No/No                                                               | 79 M    | 5.38         | 216/152                      | +4/+8                                         | −55/−37                                  | TF, native tricuspid, S3 26 mm                  | Yes/No            | 4.2                                 | Persistent CHB, Day 1 (after 24 h post-TAVI) | Dual-chamber PPM |
| 5        | Yes/No                                                              | 79 M    | 4.35         | 344/166                      | +52/+6                                        | −48/−44                                  | TF, native tricuspid, S3 26 mm                  | No/No             | 2.2                                 | Transient CHB, Day 2 | Dual-chamber PPM            |
| 6        | No/No                                                               | 77 M    | 3.32         | AF/156                       | NA/+6                                         | −68/−66                                  | TF, native tricuspid, S3 26 mm                  | No/Yes            | 2.6                                 | AF with advanced AVB, Day 13 | Dual-chamber PPM |
| 7        | No/No                                                               | 82 M    | 2.54         | 164/152                      | NA/+8                                         | 80/90                                    | TF, native tricuspid, S3 26 mm                  | No/No             | 2.7                                 | Persistent CHB, Day 14 | Dual-chamber PPM            |
| 8        | No/No                                                               | 89 M    | 4.18         | 234/126                      | −30/−6                                        | 85/51                                    | TF, native tricuspid, S3 26 mm                  | No/No             | 3.7                                 | Transient CHB, Day 2 | Dual-chamber PPM            |

AF, atrial fibrillation; CHB, complete heart block; HAVB, high-degree atrioventricular block; NA, not available; NCC, non-coronary cusp; PPM, permanent pacemaker; S3, Sapien 3; STS-PROM, Society of Thoracic Surgeons-Predicted Risk of Mortality; TAVI, transcatheter aortic valve implantation; TF, transfemoral.
In our analysis, about one-third of patients developed ΔPR interval ≥20 ms within 24 h post-TAVI, nearly 80% of whom subsequently demonstrated a ≥20 ms decrease of their PR interval within the following 24 h. Similarly, one-quarter of patients developed QRS axis change within 24 h post-TAVI, of whom about half showed QRS axis recovery towards their baseline axis within the subsequent 24 h. These findings appear consistent with prior serial ECG studies showing that the majority of BEV recipients harbour early (immediately

### Table 5 Predictive values for delayed HAVB among patients with pre-existing RBBB who did not developed HAVB within 24 h post-TAVI

| ECG changes within 24 h post-TAVI | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) |
|----------------------------------|-----------------|-----------------|-----------------------------|-----------------------------|
| ΔPR interval ≥20 ms or QRS axis change | 50.0            | 45.6            | 3.9                         | 95.3                        |
| ΔPR interval ≥20 ms (N = 157) | 20.0            | 55.9            | 1.5                         | 95.5                        |
| QRS axis change | 37.5            | 73.9            | 6.0                         | 96.4                        |

| ECG changes between 24 and 48 h post-TAVI | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) |
|-----------------------------------------|-----------------|-----------------|-----------------------------|-----------------------------|
| Persistent change of PR interval or QRS axis* | 37.5            | 81.7            | 8.3                         | 96.7                        |
| Persistent change of PR interval* (N = 157) | 0.0             | 90.8            | 0.0                         | 96.5                        |
| Persistent change of QRS axis* | 37.5            | 88.3            | 12.5                        | 97.0                        |

| Procedural factors | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) |
|--------------------|-----------------|-----------------|-----------------------------|-----------------------------|
| Pre-dilation | 50.0            | 82.8            | 11.4                        | 97.4                        |
| Implantation depth >1 mm | 100.0           | 30.6            | 6.0                         | 100.0                       |
| Implantation depth >2 mm | 100.0           | 55.6            | 9.1                         | 100.0                       |
| Implantation depth >3 mm | 62.5            | 70.6            | 8.6                         | 97.7                        |
| Pre-dilation and implantation depth >1 mm | 50.0            | 85.6            | 13.3                        | 97.5                        |
| Pre-dilation and implantation depth >2 mm | 50.0            | 88.3            | 16.0                        | 97.5                        |
| Pre-dilation and implantation depth >3 mm | 50.0            | 90.6            | 19.0                        | 97.6                        |

ECG, electrocardiogram; HAVB, high-degree atrioventricular block; TAVI, transcatheter aortic valve implantation.

*Persistent change of PR interval or QRS axis was defined as ΔPR interval ≥20 ms or QRS axis change that occurred within 24 h post-TAVI and did not show ≥20 ms decrease of PR interval or recovery to baseline QRS axis within the next 24 h, respectively.

### Figure 2 Kaplan–Meier estimates of follow-up outcomes of pre-existing right bundle branch block patients with or without the European Society of Cardiology guideline-directed electrocardiogram change after transcatheter aortic valve implantation with a balloon-expandable valve. ICD, implantable cardioverter-defibrillator; PPM, permanent pacemaker; TAVI, transcatheter aortic valve implantation.
post-TAVI) ECG change and subsequent (within 24–48 h post-TAVI) recovery.14–16 The reversibility of those ECG changes may also be related to conflicting results regarding the impact of PR prolongation in prior studies: one study identified ΔPR interval as a predictor of delayed HAVB,17 while another study did not.18 More importantly, incremental impact of those ECG changes on the HAVB risk in the presence of pre-existing RBBB has yet to be investigated—representing a unique aspect of the present analysis. Although not statistically significant in the present analysis (due to low numbers), our data do suggest that persistent ECG change (particularly, persistent QRS axis change) after 24 h post-TAVI may be more predictive for delayed HAVB than ECG changes detected only within 24 h. Further studies are required to understand the role of PR prolongation and QRS axis change in the post-TAVI risk stratification of pre-existing RBBB patients.

Relationship between procedural factors and electrophysiogram changes

Since the TAVI procedure can disturb the conduction system via balloon dilation or valve deployment, it appears theoretically reasonable that procedural factors (e.g. pre- or post-dilation and implantation depth of valve) would closely correlate with post-TAVI ECG changes (e.g. ΔPR interval, ΔQRS duration, QRS axis change). However, there is scarce data on these associations in prior studies. Interestingly, the univariable analysis in the present study found predilation and valve implantation depth relative to the NCC as potential predictors for delayed HAVB. This finding should be cautiously interpreted as it could be affected by multiple testing and was limited by a lack of multivariable adjustment. Nonetheless, the finding may be reasonable from an anatomical perspective19 because implantation depth is well established as a predictive factor,5 and predilation was reported to damage infranodal atroventricular conduction in an electrophysiological study.20

Study limitations

This is a retrospective analysis of a single, high-volume TAVI centre. Given the variability of post-TAVI PPM risk across different hospital settings, our data may not be generalizable to other institutions. This study only included BEV recipients, given the strong preponderance of BEV over SEV at our institution during the study period. Since SEVs are known to be associated with more frequent and delayed ECG changes post-TAVI15 and subsequent higher PPM risk than BEVs,8 our data should not be generalized directly to SEV recipients. Although the present study was one of the largest TAVI studies with detailed post-TAVI ECG changes in patients with pre-existing RBBB, the sample size of this study may be too small to evaluate the ESC guideline recommendations. Therefore, larger multicentre studies are warranted to confirm our findings. This study used automated measurements of the PR interval and QRS axis based on a computer-based algorithm, which may have been subject to slight measurement variability.21,22 We should note that the possibility of asymptomatic transient HAVB following hospital discharge could not be ruled out in this study because ambulatory ECG monitoring was not used routinely for all patients.

Conclusions

The present analysis evaluates the 2021 ESC guidelines for cardiac pacing in post-TAVI patients with pre-existing RBBB. While most of the HAVB events typically cluster within the first 24 h post-TAVI, delayed HAVB occurred in 4.3% in our BEV recipients with pre-existing RBBB, supporting the recommendation that early consideration of PPM and more prolonged in-patient monitoring (out to 3–4 days post-TAVI) for those patients at higher risk of delayed HAVB. However, our data failed to demonstrate an association between the proposed ESC guideline criteria (PR prolongation or QRS axis change) and heightened delayed HAVB risk. Larger prospective studies are required to validate the ESC guideline recommendations among TAVI recipients with pre-existing RBBB in the context of ECG changes and procedural factors upon delayed HAVB risk.

Lead author biography

Toshiaki Isogai, MD, MPH, had been working as a general and interventional cardiologist at Tokyo Metropolitan Tame Medical Center, Tokyo, Japan. He earned his MPH degree at The University of Tokyo in 2014. His research mainly used Japanese large-scale administrative claims and registry data. He commenced his structural heart disease research fellowship at the Cleveland Clinic, OH, USA in 2019.

Supplementary material

Supplementary material is available at European Heart Journal Open online.

Data availability statement

Data cannot be shared for ethical/privacy reasons.

Funding

This study was made possible by a generous gift from Jennifer and Robert McNeil. The funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and the preparation, review, or approval of the manuscript. I.D. was supported by the German Research Foundation (grant number: DY149/2).

Conflict of interest: none declared.

References

1. Vahanian A, Beyersdorf F, Przy F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paula R, Delgado V, Freemantle N, Gilard M, Hauga KH, Jeppsson A, Juni P, Pienaar L, Prendergast BD, Sadaba JR, Tribouilloy C, Wójcikowski W. ESC/EACTS Scientific Document Group; ESC Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632.

2. Carroll JD, Mack MJ, Vemulpalli S, Herrmann HC, Gleeson TG, Hanzel G, Deeb GM, Thurani VH, Cohen DJ, Desi N, Kirtane AJ, Fitzgerald S, Michaels J, Krohn C, Masoudi FA, Brindis RG, Bavaria JE. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol 2020;76:2492–2516.

3. Sammour Y, Krishnaswamy A, Kumar A, Pur R, Taraki KG, Bazargani N, Harb S, Griffin B, Svensson L, Wazni O, Kapadia SR. Incidence, predictors, and implications of permanent pacemaker requirement after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2021;14:115–134.

4. Rodes-Cabau J, Ellenbogen KA, Krans AD, Lavie A, Mack M, Mital S, Mustane-Carol G, Nazif TM, Soudaard L, Urena M, Windecker S, Philppton F. Management of conduction disturbances associated with transcatheter aortic
5. Glikson M, Nielsen JC, Kronborg MB, Michowitz A, Barbash IM, Bararrabes JA, Bonari G, Braunischweg F, Brignole M, Burri H, Canals AJT, Dehara JC, Delgado V, Diller GP, Israel CW, Keren A, Knoops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylen I, Tolosana JM, ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021;42:3427–3520.

6. Muntané-Carol G, del Val D, Junquera L, Faroux L, Delarochelle-Ré P, Paradis J-M, Mohammadi S, Kalavarouziotis D, Dumont E, Philippin F, Rodés-Cabau J. Timing and evolution of advanced conduction disturbances in patients with right bundle branch block undergoing transcatheter aortic valve replacement. Europace 2020;22:1537–1546.

7. Auffret V, Webb JG, Eltchaninoff H, Muñoz-García AJ, Himbert D, Tamburino C, Nombela-Franco L, Nietlispach F, Maris C, Ruel M, Dager AE, Serra V, Cheema AN, Amat-Santos IJ, de Brito FS, Lemos PA, Abizaid A, Sarmento-Leite R, Dumont E, Barbanti M, Durand E, Alonso Brailas JH, Vanhain A, Bouleti C, Immi S, Masiino F, del Valle R, Benitez LM, Garcia del Blanco B, Pur P, Philippin F, Urena M, Rodés-Cabau J. Clinical impact of baseline right bundle branch block in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Inter 2017;10:1564–1574.

8. Vlasta W, Chandrasekhar J, Muñoz-García AJ, Tchetche D, de Brito FS Jr, Barbanti M, Kornowski R, Latib A, D’Onofrio A, Ribichini F, Baan J, Tijssen JGP, Trillo-Nouche R, Dumontei N, Abizaid A, Sartori S, D’Errico P, Tarantini G, Lunardi M, Orvin K, Pagani M, Del Valle R, Modone T, Dansa G, Mehran R, Piek JJ, Delevi R. Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transmembranous aortic valve implantation: from the CENTER-collaboration. Eur Heart J 2019;40:456–465.

9. Srawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, Rautaharju PM, van Herpen G, Wagner GS, Wellens H, American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation; Heart Rhythm Society. AHA/ACC/HR recommendations for the standardization and interpretation of the electrocardiogram: Part III: Intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009;53:976–981.

10. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JR, Kim RJ, Lee R, Marine JE, McLeod CJ, Okin PM, Patton KK, Pellegrini CN, Selman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019;74:e51–e156.

11. Hansson NC, Norgaard BL, Barbanti M, Nielsen NE, Yang TH, Tamburino C, Dvir D, Jišlahávi H, Blanke P, Malikar RR, Latib A, Colombo A, Tarantini G, Raju R, Wood D, Andersen HR, Ribiero HB, Kapadia S, Min J, Feuchtner G, Gurvitch R, Algoofi F, Pelletier M, Ussia GP, Napadeno M, Sandoli de Brito F Jr, Kodali S, Pache G, Canovas SJ, Berger A, Murphy D, Svensson LG, Rodes-Cabau J, Leon MB, Webb JG, Leipsic J. The impact of calcium volume and distribution in aortic root injury related to balloon-expandable transcatheter aortic valve replacement. J Cardiovasc Comput Tomogr 2019;13:382–392.

12. Blanke P, Wilson AB, Webb JG, Achenbach S, Piazza N, Min JK, Pache G, Leipsic J. Oversizing in transcatheter aortic valve replacement, a commonly used term but a poorly understood one: dependency on definition and geometrical measurements. J Cardiovasc Comput Tomogr 2014;8:67–76.

13. Saint Croix GR, Lacy SC, Hirschian H, Beohar N. Clinical impact of preexisting right bundle branch block after transcatheter aortic valve replacement: a systematic review and meta-analysis. J Interv Cardiol 2020;2020:1–8.

14. Leire U, Eulogio G, Francisco JRR, Francisco JPV, Juan MP, Belen DA, Miguel RDR, Adolfo F, Rodrigo T, Belen RA. Electrocardiographic changes and conduction disturbances after transfemoral aortic valve implantation with Edwards Sapien 3 prosthesis. J Electrocardiol 2018;51:416–421.

15. Coeman M, Kayaert P, Philipsen T, Calle S, Gheeraert P, Gevaert S, Czapla J, Timmers L, Van Heusdeny V, De Pooster J. Different dynamics of new-onset electrocardiographic changes after balloon- and self-expandable transcatheter aortic valve replacement: implications for prolonged heart rhythm monitoring. J Electrocardiol 2020;59:68–73.

16. Eikis A, Gul M, Uyarel H, Surgit O, Yıldırım A, Uslu N, Aksu H, Turen S, Uzun F, Satilmisoglu H, Erös MK, Bakır I. Electrophysiological evaluation of atrioventricular conduction disturbances in transcatheter aortic valve implantation with Edwards SAPIEN prosthesis. J Invasive Cardiol 2013;25:305–309.

17. Mangieri A, Lanzillo G, Bertoldo J, Jabbari RJ, Regazzoli D, Ancona MB, Tanaka A, Mitomo S, Garducci S, Montalto C, Pagani M, Giannini F, Giglio M, Montorfano M, Cheffo A, Rodes-Cabau J, Monaco F, Pagliolo G, Della Bella P, Colombo A, Latib A. Predictors of advanced conduction disturbances requiring a late (> =48 h) permanent pacemaker following transcatheter aortic valve replacement. JACC Cardiovasc Inter 2018;11:1519–1526.

18. Jørgensen TH, De Backer O, Gerds TA, Bieiauskas G, Svendsen JH, Søndergaard L. Immediate post-procedural 12-lead electrocardiography as predictor of late conduction defects after transcatheter aortic valve replacement. JACC Cardiovasc Inter 2019;11:1509–1518.

19. Plazza N, de Jagere P, Schultz C, Becker AE, Serruys PW, Anderson RH. Anatomy of the aortic valve complex and its implications for transcatheter implantation of the aortic valve. Circ Cardiovasc Inter 2008;1:74–81.

20. Reiter C, Lambert T, Kellermair J, Blissberger H, Felliner A, Strasser B, Grund M, Nahler A, Steinwender C. Intraprocedural dynamics of cardiac conduction during transcatheter aortic valve implantation: assessment by simultaneous electro-physiological testing. Heart Rhythm 2021;18:419–425.

21. Burke GM, Wang N, Bliese S, Levy D, Magnani JW. Assessment of reproducibility–automated and digital caliper ECG measurement in the Framingham Heart Study. J Electrocardiol 2014;47:288–293.

22. Kligfield P, Badili F, Denjoy I, Babaev S, Clark E, De Bie J, Devine B, Extramiana F, Generali G, Gregg R, Helfenbein E, Kors J, Leber R, Macfarlane P, Maison-Blanche P, Rawlansdon I, Schmid R, Vaglio M, van Herpen G, Xue J, Young B, Green CL. Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs. Am Heart J 2018;200:1–10.